Chairman of the Board
Bob has served on Akoya Bioscience’s board since the company’s inception in 2015. Bob was a founder and served as a Managing Director of Telegraph Hill Partners (THP), a growth equity/late-stage venture capital investment firm focused exclusively on healthcare related companies, since its founding in 2001 until August 2020 when he became Partner Emeritus. Prior to THP, Bob was a principal in the investment firm of Mackowski & Shepler and an officer in the investment banking division of Merrill Lynch & Co. In addition to Akoya Biosciences, Bob currently serves on the boards of Agena Biosciences, Inc. and Dynex Technologies, Inc. Previously, Bob served on the boards of Kinetikos Medical (acquired by Integra), AcroMetrix, Inc. (acquired by Life Technologies), Aurora Discovery, Inc. (acquired by NEXUS Biosystems), Applied Precision (acquired by GE), LDR Holding Corporation (NASDAQ:LDRH), Endoscopic Technologies, Inc. (acquired by AtriCure), Sage Labs, Inc. (acquired by Horizon Discovery), Vidacare Corporation (acquired by Teleflex), ReloAction, Inc. (acquired by Hewitt Associates), Microinterventional Systems, Inc. (acquired by Medtronic), Reading Glass Company, Inc., One Body, Inc., R.D. Percy & Company, RareCyte, Inc. and was chairman of Genomics Solutions, Inc. (NASDAQ: GNSL). He also was a board observer at Magstim, Inc. and Precision Nanosystems, Inc. (acquired by Danaher). Bob received a BA from Duke University and an MBA from New York University.
Thomas Raffin, MD
Tom has served on the Akoya Board of Directors since the inception of Akoya Biosciences. Tom spent 24 years on the faculty at Stanford University School of Medicine where he remains the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics, former Chief of Pulmonary and Critical Care Medicine, and Co-Founder and Director Emeritus of the Stanford University Center for Biomedical Ethics. Over the past two decades he has worked extensively in the healthcare and medical device sectors and is a co-founder of Rigel Pharmaceuticals. In addition to Akoya, Tom has represented THP on the boards AngioScore (acquired by Spectranetics), Aquaro, Confirma (acquired by Merge), LDR Spine (NASDAQ:LDRH), PneumRx (acquired by BTG Plc), Freedom Innovations (acquired by Health Evolution Partners) and Magstim. He was an observer on the boards of Estech (acquired by AtriCure) and Vidacare (acquired by Teleflex). Tom received a BA from Stanford University and an M.D. from Stanford University School of Medicine and completed his medical residency at the Peter Bent Brigham Hospital in Boston.
Matthew Winkler, Ph.D.
Dr. Winkler has served on our board of directors since July 2017. Dr. Winkler is the former Chairman and founder of Asuragen. Asuragen was sold in 2021 to Bio-Techne. He also founded Mirna Therapeutics(MIRN) (merged with Synlogic 2017) and Ambion, Inc. Ambion was acquired in 2006 by Applied Biosystems, now Thermo Fisher Scientific. Dr. Winkler currently serves on the board of directors of “The Breakthrough Institute”, “Revive and Restore” and KLRU Television, all from 2017 to present. Dr. Winkler was an Assistant and Associate Professor (1983-1991) in the Department of Zoology at the University of Texas at Austin, where he is also currently a member of several advisory boards. Dr. Winkler received his B.S. in Genetics and a Ph.D. in Zoology from the University of California at Berkeley. The board of directors believes that Dr. Winkler is qualified to serve on our board of directors due to his extensive operational experience with global life sciences companies, and particularly his expertise in business development and corporate strategy.
Garry Nolan, PhD
Founder Board Member & Head of the Scientific Advisory Board
Garry co-founded Akoya Biosciences in 2015, and is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine. As a co-inventor of the CODEX technology, Garry has focused his research efforts on developing novel technologies and computational methods for research into cancer, leukemia, immunology and autoimmune disease. Dr. Nolan was the founder of a number of life sciences companies in addition to Akoya, including Rigel Inc. (NASDAQ: RIGL) and DVS Sciences and serves as an advisor and board member for several biotechnology companies. He has published over 220 research articles and is the holder of 20 US patents, and has been honored as one of the top 25 inventors at Stanford University. He trained with Leonard Herzenberg (for his Ph.D.) and Nobelist Dr. David Baltimore. Garry is the first recipient of the Teal Innovator Award (2012) from the Department of Defense and has been honored with a number of awards including Nature Publishing “Outstanding Research Achievement”, Stohlman Scholar from the Leukemia and Lymphoma Society and Burroughs Wellcome Fund New Investigator Award.